(5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors. 2020

Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China.

As rate-limited enzyme of polyol pathway, aldose reductase (ALR2) is one of the key inhibitory targets for alleviating diabetic complications. To reduce the toxic side effects of the inhibitors and to decrease the level of oxidative stress, the inhibitory selectivity towards ALR2 against detoxicating aldehyde reductase (ALR1) and antioxidant activity are included in the design of multifunctional ALR2 inhibitors. Hydroxypyridinone derivatives were designed, synthesized and evaluated their inhibitory behavior and antioxidant activity. Notably, {2-[2-(3,4-dihydroxy-phenyl)-vinyl]-5-hydroxy-4-oxo-4H-pyridin-1-yl}-acetic acid (7l) was the most potent, with IC50 values of 0.789 μM. Moreover, 7l showed excellent selectivity towards ALR2 with selectivity index 25.23, which was much higher than that of eparlestat (17.37), the positive control. More significantly, 7l performed powerful antioxidative action. At a concentration of 1 μM, phenolic compounds 7l scavenged DPPH radical with an inhibitory rate of 41.48%, which was much higher than that of the well-known antioxidant Trolox, at 11.89%. Besides, 7l remarkably suppressed lipid peroxidation with a rate of 88.76% at a concentration of 100 μM. The binding mode derived from molecular docking proved that the derivatives were tightly bound to the activate site, suggesting strongly inhibitory action of derivatives against ALR2. Therefore, these results provided an achievement of multifunctional ALR2 inhibitors capable with potency for both selective ALR2 inhibition and as antioxidants.

UI MeSH Term Description Entries
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085 Acetates Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure. Acetate,Acetic Acid Esters,Acetic Acids,Acids, Acetic,Esters, Acetic Acid
D000449 Aldehyde Reductase An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. Aldose Reductase,Aldose Reductase Ia,Aldose Reductase Ib,Erythrose Reductase,Xylose Reductase,Reductase Ia, Aldose,Reductase Ib, Aldose,Reductase, Aldehyde,Reductase, Aldose,Reductase, Erythrose,Reductase, Xylose
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
December 2020, Chemico-biological interactions,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
April 2003, Journal of medicinal chemistry,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
March 2012, Acta crystallographica. Section E, Structure reports online,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
September 2001, European journal of medicinal chemistry,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
March 1986, Chemical & pharmaceutical bulletin,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
November 2011, Acta crystallographica. Section E, Structure reports online,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
June 2011, Archiv der Pharmazie,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
April 2005, Acta crystallographica. Section C, Crystal structure communications,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
January 2005, Bioorganic & medicinal chemistry,
Huan Chen, and Xin Zhang, and Xiaonan Zhang, and Wenchao Liu, and Yanqi Lei, and Changjin Zhu, and Bing Ma
August 2007, Die Pharmazie,
Copied contents to your clipboard!